HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 1,489-1,500 of 4,505
Device study icon
CompletedNCT03880227

Improving Visual Attention in Schizophrenia

Official study title

Improving Visual Attention to Social Stimuli in Individuals With Schizophrenia

This study has finished and is no longer accepting participants.

In Richardson
SchizophreniaDevice studyAges 18–60
Countries
United States
Sponsor
The University of Texas at Dallas
Drug study icon
CompletedNCT00797277

Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia

Official study title

An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia

This study has finished and is no longer accepting participants.

In Taipei
SchizophreniaMedication studyAges 18–65
Countries
Taiwan
Sponsor
National Taiwan University Hospital
Behavioral study icon
CompletedNCT02398279

L-arginine add-on Therapy in people with Schizophrenia

Official study title

L-Arginine add-on Treatment for Schizophrenia: A Randomized, Double Blind, Placebo Controlled, Cross Over Study

This study has finished and is no longer accepting participants.

In Ankara
SchizophreniaPlacebo researchAges 18–65
Countries
Türkiye
Sponsor
Hacettepe University
Drug study icon
CompletedNCT00177177

L-carnosine for Schizophrenia

Official study title

L-Carnosine, an Antioxidant and AGE Inhibitor (Advanced Glycation End Products) for Cognitive Enhancement Among Persons With Schizophrenia: A Randomized, Add-on Double-Blind, Placebo Controlled, Clinical Trial

This study has finished and is no longer accepting participants.

Multiple locations, including Bridgeville
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
University of Pittsburgh
Drug study icon
CompletedNCT00132314

Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

Official study title

CSP #555 - Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Tuscaloosa
SchizophreniaMedication studyAges 18+
Countries
United States
Sponsor
US Department of Veterans Affairs
Other study type icon
CompletedNCT07447960

LRFN5 and OLFM4 in Schizoaffective Disorder

Official study title

LRFN5 and OLFM4 Levels in Schizoaffective Disorder: A Cross-Sectional Case-Control Study

This study has finished and is no longer accepting participants.

In Elâzığ
SchizophreniaObservational studyAges 18–65
Countries
Türkiye
Sponsor
Elazığ Mental Health and Diseases Hospital

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.